ENXTPA:MEDCLPharmaceuticals
MedinCell (ENXTPA:MEDCL) Secures €28 Million In Loans, Is The Discount Too Wide?
MedinCell (ENXTPA:MEDCL) drew investor attention after securing €28 million in non dilutive bank loans from European lenders, extending debt maturities to mid 2031 and planning early repayment of part of its EIB facility.
See our latest analysis for MedinCell.
These financing moves come after a period of strong momentum for MedinCell, with a 90 day share price return of 13.74% and a 1 year total shareholder return of 50.72%, while the 3 year total shareholder return is more than 3 times the...